Letermovir reduces chronic GVHD risk in calcineurin inhibitor-free GVHD prophylaxis after hematopoietic cell transplantation

Blood Adv. 2022 May 24;6(10):3053-3057. doi: 10.1182/bloodadvances.2021006213.
No abstract available

MeSH terms

  • Acetates
  • Calcineurin Inhibitors / therapeutic use
  • Graft vs Host Disease* / drug therapy
  • Graft vs Host Disease* / etiology
  • Graft vs Host Disease* / prevention & control
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Quinazolines

Substances

  • Acetates
  • Calcineurin Inhibitors
  • Quinazolines
  • letermovir